Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects
- PMID: 1531780
- DOI: 10.1002/1097-0142(19920315)69:6<1492::aid-cncr2820690630>3.0.co;2-3
Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects
Abstract
Doxorubicin is an effective antineoplastic agent, but it frequently causes dose-related cardiotoxic effects. Because the atrial natriuretic peptide (ANP) level is elevated in children with heart defects, the authors measured the ANP levels in children to determine whether ANP might serve as a simple diagnostic indicator of cardiotoxic effects. Sixteen patients, 5 to 19 years of age, who were being treated with doxorubicin (45 mg/m2 body surface area) for various malignancies had ANP levels measured in plasma. There was a group of six children, with a significant peak of plasma ANP (pANP) levels 3 weeks after the administration of the drug. Of these six patients, five had received high cumulative doses of doxorubicin (160 to 370 mg/m2), and two of them went into congestive heart failure without a previous decline in left ventricular ejection fraction, a standard technique for monitoring cardiac function during treatment with doxorubicin. The other ten patients had normal ANP levels throughout the study, and signs of cardiac dysfunction did not develop. None of the patients in the control group who had cancer and were not treated with doxorubicin and none of the healthy volunteers had elevated ANP levels. These preliminary results suggest that pANP may be useful as an early and sensitive indicator for doxorubicin-related myocardial damage.
Similar articles
-
Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer.Med Pediatr Oncol. 2001 Jul;37(1):4-9. doi: 10.1002/mpo.1155. Med Pediatr Oncol. 2001. PMID: 11466716
-
Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients.Clin Sci (Lond). 2001 Dec;101(6):601-7. Clin Sci (Lond). 2001. PMID: 11724646 Clinical Trial.
-
Serum N-terminal atrial natriuretic peptide (NT-ANP) in the cardiac follow-up in children with cancer.Med Pediatr Oncol. 1998 Aug;31(2):73-8. doi: 10.1002/(sici)1096-911x(199808)31:2<73::aid-mpo5>3.0.co;2-w. Med Pediatr Oncol. 1998. PMID: 9680930
-
Use of cardiac markers for monitoring of doxorubixin-induced cardiotoxicity in children with cancer.J Pediatr Hematol Oncol. 2012 Nov;34(8):589-95. doi: 10.1097/MPH.0b013e31826faf44. J Pediatr Hematol Oncol. 2012. PMID: 23018571 Clinical Trial.
-
Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet).Breast. 2009 Aug;18(4):218-24. doi: 10.1016/j.breast.2009.05.004. Epub 2009 Aug 4. Breast. 2009. PMID: 19656681 Review.
Cited by
-
Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Clin Biochem. 2015 Mar;48(4-5):223-35. doi: 10.1016/j.clinbiochem.2014.10.013. Epub 2014 Nov 7. Clin Biochem. 2015. PMID: 25445234 Free PMC article. Review.
-
Myocardial protective effect of tezosentan, an endothelin receptor antagonist, for ischemia-reperfusion injury in experimental heart failure models.J Korean Med Sci. 2009 Oct;24(5):782-8. doi: 10.3346/jkms.2009.24.5.782. Epub 2009 Sep 23. J Korean Med Sci. 2009. PMID: 19794971 Free PMC article.
-
Alternative Biomarkers for Combined Biology.Heart Fail Clin. 2017 Apr;13(2):381-401. doi: 10.1016/j.hfc.2016.12.009. Heart Fail Clin. 2017. PMID: 28279423 Free PMC article. Review.
-
Anthracycline antibiotics in cancer therapy. Focus on drug resistance.Drugs. 1994 Feb;47(2):223-58. doi: 10.2165/00003495-199447020-00002. Drugs. 1994. PMID: 7512899 Review.
-
Troponins and Natriuretic Peptides in Cardio-Oncology Patients-Data From the ECoR Registry.Front Pharmacol. 2020 May 19;11:740. doi: 10.3389/fphar.2020.00740. eCollection 2020. Front Pharmacol. 2020. PMID: 32508657 Free PMC article.